APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
OFEV® slows FVC decline regardless of baseline FVC impairment
Document ID: PC-MY-100887
05/03/2021
Author: Boehringer Ingelheim
This is the 1st data published from INPULSIS-ON (open-label extension trial) on anti-fibrotic use in severely impaired FVC patients with IPF. [1]
References:
1. Wuyts WA, et al. Lung. 2016;194:731-743.
RELATED CONTENT
PC-MY-100887
Production date: March 2021
Production date: March 2021
